GLADEL - Grupo Latino Americano de Estudio de Lupus

Biomarkers in Systemic Lupus Erythematosus

Launching the GLADEL 2.0 Study Group

 

History

GLADEL has more than 20 years of sustained work with a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region.

 

Objective

A new generation of “Lupus Investigators” throughout Latin America launched a novel study that aim to identify subgroups of patients with SLE, based on demographic and clinical profile, serum and urinary biomarkers and transcriptome studies using blood and tissue RNA to identify potential transcriptional signatures.
 

 

GLADEL 2.0 Cohort. Study design.

Latin-American registry.

 

  • ~150 investigators
  • 42 centers
  • 10 countries
  • 2,100 individuals
    • 1,050 SLE patients
    • 1,050 controls (healthy non-relative control at ratio 1:1, matched by age (± 5 years), sex and ethnic group)
  • +500 variables (sociodemographic, clinical and patients reported outcomes)
  • Centralize analysis of:
    • Serological biomarkers
    • Urinary biomarkers
    • Transcriptome

 

 

 

 

 

 

Highlighted Contents

Publications

Publications

More than 80 publications in peer reviewed journals.

Learn more
BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS

BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS

A novel study launched by the nextgen of investigators.

Learn more
Education for physicians

Education for physicians

A new educational program about lupus

Learn more
Let's talk about Lupus

Let's talk about Lupus

Topics and frequently asked questions selected by patients.

Learn more